Ultragenyx Pharmaceutical Chief Accounting Officer Theodore Alan Huizenga sold 1,283 shares at $13.57 per share on September 15, 2026. For investors, the transaction represented about 1.9% of his prior holding, while his disclosed ownership after the sale stood at 67,863 shares.
Key Highlights
- The transaction was recorded on 15 September 2026.
- Theodore Alan Huizenga is Ultragenyx Pharmaceutical’s Chief Accounting Officer.
- The filing reports SEC transaction code S.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Chief Accounting Officer Theodore Alan Huizenga sold 1,283 shares at $13.57 per share. The transaction was completed on 15 September 2026.
Ultragenyx Insider Transaction Details
Huizenga serves as Ultragenyx Pharmaceutical’s Chief Accounting Officer. The transaction was classified under SEC code S. The sale involved shares of Ultragenyx Pharmaceutical. Huizenga’s position following the transaction is addressed separately below.
Sale Represents 1.9% of Prior Holding
The transaction represented about 1.9% of Huizenga’s prior Ultragenyx Pharmaceutical shareholding. His ownership after the transaction stood at 67,863 shares. The 1.9% figure compares the sale with his holdings before the transaction.
FAQs
Q: Why did the Ultragenyx Pharmaceutical insider sell shares?
A: The article does not state why Huizenga sold the shares. It states only that he sold 1,283 shares at $13.57 per share on 15 September 2026.
Q: How many Ultragenyx shares does Theodore Alan Huizenga own after the sale?
A: Theodore Alan Huizenga owned 67,863 Ultragenyx Pharmaceutical shares after the transaction. The sale represented about 1.9% of his prior holding.
Q: What does SEC transaction code S mean for the Ultragenyx sale?
A: The Ultragenyx Pharmaceutical transaction was classified under SEC code S. It involved 1,283 shares sold at $13.57 per share by Theodore Alan Huizenga.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.